Literature DB >> 10708285

Adherence to HAART in French HIV-infected injecting drug users: the contribution of buprenorphine drug maintenance treatment. The Manif 2000 study group.

J P Moatti1, M P Carrieri, B Spire, J A Gastaut, J P Cassuto, J Moreau.   

Abstract

OBJECTIVES: To assess adherence to highly active antiretroviral therapies (HAART) in a cohort of French patients infected by HIV through injection drug use (IDU), and the impact on adherence of buprenorphine ambulatory drug maintenance treatment (DMT) which has been widely introduced since 1996.
DESIGN: Adherence assessment at first visit after initiation of HAART in the MANIF2000 cohort study.
METHODS: Patient's face-to-face and self-administered questionnaires. Univariate and logistic regression adjusted odds ratios (OR) to compare characteristics of non-adherent versus adherent patients.
RESULTS: Of the 164 patients, 34.8% took less than 80% of the prescribed HAART doses during the previous week. Decrease in viral load titres after initiation of HAART was significantly lower among non-adherent patients. After adjustment by logistic regression, non-adherence was associated with younger age, alcohol consumption, frequency of negative life-events during the prior 6 months and active drug use. However, IDU in buprenorphine DMT reached higher levels of adherence (78.1%) than ex-IDU (65.5%), although this difference did not reach statistical significance.
CONCLUSION: Prescription of buprenorphine DMT may increase adherence to HAART among HIV-infected opiate-dependent patients. Reducing the negative impact of stressful life-events through psychosocial interventions should be considered, even for those who have stopped using drugs.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10708285     DOI: 10.1097/00002030-200001280-00010

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  60 in total

1.  Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring.

Authors:  J H Arnsten; P A Demas; H Farzadegan; R W Grant; M N Gourevitch; C J Chang; D Buono; H Eckholdt; A A Howard; E E Schoenbaum
Journal:  Clin Infect Dis       Date:  2001-09-05       Impact factor: 9.079

2.  Is it justifiable to withhold treatment for hepatitis C from illicit-drug users?

Authors:  B R Edlin; K H Seal; J Lorvick; A H Kral; D H Ciccarone; L D Moore; B Lo
Journal:  N Engl J Med       Date:  2001-07-19       Impact factor: 91.245

3.  Young age predicts poor antiretroviral adherence and viral load suppression among injection drug users.

Authors:  Scott E Hadland; M-J Milloy; Thomas Kerr; Ruth Zhang; Silvia Guillemi; Robert S Hogg; Julio S Montaner; Evan Wood
Journal:  AIDS Patient Care STDS       Date:  2012-03-19       Impact factor: 5.078

4.  Reason and rights in global drug control policy.

Authors:  Richard Elliott; Joanne Csete; Anita Palepu; Thomas Kerr
Journal:  CMAJ       Date:  2005-03-01       Impact factor: 8.262

Review 5.  Self-report measures of antiretroviral therapy adherence: A review with recommendations for HIV research and clinical management.

Authors:  Jane M Simoni; Ann E Kurth; Cynthia R Pearson; David W Pantalone; Joseph O Merrill; Pamela A Frick
Journal:  AIDS Behav       Date:  2006-05

6.  Age-associated predictors of medication adherence in HIV-positive adults: health beliefs, self-efficacy, and neurocognitive status.

Authors:  Terry R Barclay; Charles H Hinkin; Steven A Castellon; Karen I Mason; Matthew J Reinhard; Sarah D Marion; Andrew J Levine; Ramani S Durvasula
Journal:  Health Psychol       Date:  2007-01       Impact factor: 4.267

7.  Association between risk behaviors and antiretroviral resistance in HIV-infected patients receiving opioid agonist treatment.

Authors:  Jeanette M Tetrault; Michael J Kozal; Jennifer Chiarella; Lynn E Sullivan; An T Dinh; David A Fiellin
Journal:  J Addict Med       Date:  2013 Mar-Apr       Impact factor: 3.702

8.  Barriers to antiretroviral treatment access for injecting drug users living with HIV in Chennai, South India.

Authors:  Venkatesan Chakrapani; Jaikumar Velayudham; Murali Shunmugam; Peter A Newman; Robert Dubrow
Journal:  AIDS Care       Date:  2013-11-28

9.  The causal effect of opioid substitution treatment on HAART medication refill adherence.

Authors:  Bohdan Nosyk; Jeong E Min; Guillaume Colley; Viviane D Lima; Benita Yip; M-J S Milloy; Evan Wood; Julio S G Montaner
Journal:  AIDS       Date:  2015-05-15       Impact factor: 4.177

10.  The impact of neuropsychological functioning on adherence to HAART in HIV-infected substance abuse patients.

Authors:  Allison J Applebaum; Laura C Reilly; Jeffrey S Gonzalez; Mark A Richardson; Catherine L Leveroni; Steven A Safren
Journal:  AIDS Patient Care STDS       Date:  2009-06       Impact factor: 5.078

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.